Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure

Gilotra, Nisha A.; Princewill, Oluseyi; Marino, B; Okwuosa, Ike S.; Chasler, Jessica; Almansa, Johana; Cummings, Abby; Rhodes, Parker; Chambers, Julianne; Cuomo, Kimberly; Russell, Stuart D.

doi:10.1016/j.jchf.2017.10.001

Cited by 58 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TRANSFORM‐HF will assess the superiority of torsemide in comparison to furosemide in reducing all‐cause mortality. Furthermore, ongoing studies are testing the effect of subcutaneous furosemide in comparison to oral furosemide …”

Section: Gaps In Knowledge and Future Directionsmentioning

confidence: 99%

The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

Mullens

Damman

Harjola

et al. 2019

European J of Heart Fail

721

697

View full text Add to dashboard Cite

The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving a state of euvolaemia, mainly through the use of diuretic therapy. The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. This position paper focuses on the use of diuretics in heart failure with congestion. The manuscript addresses frequently encountered challenges, such as (i) evaluation of congestion and clinical euvolaemia, (ii) assessment of diuretic response/resistance in the treatment of acute heart failure, (iii) an approach towards stepped pharmacologic diuretic strategies, based upon diuretic response, and (iv) management of common electrolyte disturbances. Recommendations are made in line with available guidelines, evidence and expert opinion.

show abstract

Section: Gaps In Knowledge and Future Directionsmentioning

confidence: 99%

The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

Mullens

Damman

Harjola

et al. 2019

European J of Heart Fail

721

697

View full text Add to dashboard Cite

show abstract

“…There are several trials ongoing, including ADVOR (testing acetazolamide – NCT03505788), TRANSFORM‐HF (testing torsemide vs. furosemide – NCT03296813), EMPA‐RESPONSE‐AHF (testing empagliflozin in acute HF – NCT03200860), and a trial of metolazone vs. chlorothiazide (NCT03574857). The development of user‐friendly systems to deliver subcutaneous furosemide will require evaluation in clinical trials …”

Section: Pharmacotherapymentioning

confidence: 99%

“…The development of user-friendly systems to deliver subcutaneous furosemide will require evaluation in clinical trials. 38,39…”

Section: Supporting Evidencementioning

confidence: 99%

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Seferović

Ponikowski

Anker

et al. 2019

European J of Heart Fail

540

422

View full text Add to dashboard Cite

The European Society of Cardiology (ESC) has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the Heart Failure Association (HFA) of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held

show abstract

“…Aiming to further reduce healthcare utilization and to improve quality of life, a novel, pH-neutral subcutaneous formulation of furosemide has recently been developed. In a small, phase II, proof of concept study, a total of 80 mg furosemide was injected under the skin over 5 hours using an automated infusion pump (35). Upon direct comparison to a dose adjusted, single traditional IV furosemide injection, the new formulation provided comparable urine output with a more sustained diuretic effect.…”

Section: Subcutaneous Furosemide Therapymentioning

confidence: 99%

Telemonitoring and Contemporary Outpatient Management of Patients with Heart Failure: Is it Time?

Alexy¹,

Francis²

2018

Cardiologia Hungarica

View full text Add to dashboard Cite

Chronic heart failure is not going away, but continues to expand globally. This is largely driven by new cases of heart failure with preserved ejection fraction. Patients receive chronic disease management complicated by frequent hospitalizations to treat episodes of exacerbation that not only affect quality of life but is also associated with a signifi cant fi nancial burden to the society. With a better understanding of heart failure pathophysiology, our management strategy has shifted progressively from reactive to preventive, such as daily weight monitoring and interaction with specialized nurses. With the advent of new technology, non-invasive remote monitoring is now more available with regular, automatic data transmission to the health care center, including heart rate, blood pressure, weight and daily activity. The widespread use of implanted cardioverter defi brillators and cardiac resynchronization therapy in patients with heart failure has enabled the expansion of these devices with various indwelling sensors aimed at monitoring volume status and predicting need for hospitalization. As the success of this approach was noted to be limited, implantable hemodynamic sensors have been subsequently developed in an attempt to reduce heart failure hospitalizations and mortality. This manuscript provides a brief review and clinical utility of the available remote monitoring approaches and devices for patients with heart failure. Újabb lehetőségek a telemonitorozás és a krónikus szívelégtelenség ambuláns kezelésében A krónikus szívelégtelenség incidenciája világszerte emelkedik elsődlegesen az újonnan diagnosztizált megtartott ejekciós frakciójú szívelégtelenségben szenvedő betegek magas számának köszönhetően. A szívelégtelen betegek krónikus ellátást és gyakori kórházi kezelést igényelnek, amely nemcsak az életminőségre van negatív hatással, de a társadalomra is jelentős anyagi terhet ró. A szívelégtelenség patofi ziológiájának megismerésével párhuzamosan terápiás stratégiánk egyre inkább a reaktív felől a preventív felé tolódott, mint például a testsúly napi követése és a szívelégtelenség ellátásában jártas nővérekkel való rendszeres kapcsolattartás. A technológia fejlődésével noninvaziv telemonitorozás is lehetővé vált, amely rendszeresen és automatikusan továbbít bizonyos paramétereket az egészségügyi centrumba, mint például szívfrekvencia, vérnyomás, testsúly és napi aktivitás. A defi brillátorok és reszinkronizációs terápia elterjedése lehetővé tette különböző szenzorok integrálását, amelyek alkalmasak lehetnek a folyadékfelesleg monitorozására és emiatti kórházi felvétel szükségességének előre történő megjóslására. Mivel ezen módszerek sikere limitáltnak bizonyult, implantálható hemodinamikai monitorok kerültek kifejlesztésre, melyek használata a szívelégtelenség miatti halálozás és kórházi felvételek számának csökkenéséhez vezetett. Ezen közlemény a szívelégtelenségben szenvedő betegpopuláció számára rendelkezésre álló invazív és noninvazív telemonitorozási lehetőségeket, valamint az ezekkel elért eredmé...

show abstract

Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure

Cited by 58 publications

References 15 publications

The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Telemonitoring and Contemporary Outpatient Management of Patients with Heart Failure: Is it Time?

Contact Info

Product

Resources

About